Navigating the landscape of end-of-life care and access to medications like this drug in New South Wales, the state, requires a careful grasp of the intricate legal system. Currently, this powerful sedative does not have a approved place on the Pharmaceutical Benefits Scheme (PBS) and is therefore not commonly prescribed by clinical professionals.